Nicholas Zareifopoulos
Research Subjects
Research Interests
Nicholas Zareifopoulos has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Dimitrios Velissaris
Internal Medicine Department, University Hospital of Patras, Greece
5 shared publications D. Velissaris
Univ Patras, Dept Internal Med, Sch Med, Athens, Greece
4 shared publicationsM. Lagadinou
Univ Gen Hosp Patras, Emergency Dept, Athens, Greece
4 shared publications- Anastasia Karela
Emergency Department, University Hospital of Patras.
3 shared publications - Maria Lagadinou
Department of Internal Medicine, Medical School, University of Patras, 26504 Patras, Greece
3 shared publications A. Dimitriou
Gen Hosp Nikea & Pireus Hagios Panteleimon, Dept Psychiat, Patras, Greece
2 shared publications
Latest Publications
- 23 February 2022
- Published by Taylor & Francis in Hospital Practice
- Vol. 50 (2) , 102-103
Burnout for medical professionals during the COVID-19 pandemic in Greece; the role of primary care
The Greek state funded national health system is organized around tertiary care hospitals, with primary care being provided primarily by private practice physician. This leads to significant inequa...
- 23 February 2022
- Published by Taylor & Francis in Hospital Practice
- Vol. 50 (2) , 102-103
Burnout for medical professionals during the COVID-19 pandemic in Greece; the role of primary care
The Greek state funded national health system is organized around tertiary care hospitals, with primary care being provided primarily by private practice physician. This leads to significant inequa...
- Open Access
- 13 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Presepsin as a Diagnostic and Prognostic Biomarker in Sepsis
Sepsis is a condition characterized by high morbidity and mortality which is commonly encountered in an emergency and critical care setting. Despite a substantial body of research, the ideal biomarker for the diagnosis and prognostic stratification of septic patients remains unknown. This review aimed to summarize the publications referring to the validity of the biomarker presepsin when used for the detection, monitoring and prognosis in patients suffering with sepsis. This work is a narrative review based on a PubMed/Medline search conducted in order to identify all relevant publications referring to the use of presepsin in sepsis. Search was not limited by year of publication so all articles archived in the database would be retrieved. No article from before 2010 was identified. A total of 57 publications of the last decade were included, all of which support the use of presepsin as a biomarker for the assessment of septic patients. It has been used alone or in combination with commonly used biomarkers in the evaluation of patients with sepsis in settings such as the emergency department and the intensive care unit. It is useful in the initial workup of patients with suspected sepsis in the emergency setting and may be a predictive factor of mortality and the most severe complication of sepsis. Presepsin seems to be a valuable tool for the laboratory workup of sepsis, especially when used in conjunction with other biomarkers and clinical rating scores with an established role in this population. Further research is needed to evaluate the clinical implications of utilizing presepsin measurements in the workup of sepsis.
- 13 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessPresepsin as a Diagnostic and Prognostic Biomarker in Sepsis
Sepsis is a condition characterized by high morbidity and mortality which is commonly encountered in an emergency and critical care setting. Despite a substantial body of research, the ideal biomarker for the diagnosis and prognostic stratification of septic patients remains unknown. This review aimed to summarize the publications referring to the validity of the biomarker presepsin when used for the detection, monitoring and prognosis in patients suffering with sepsis. This work is a narrative review based on a PubMed/Medline search conducted in order to identify all relevant publications referring to the use of presepsin in sepsis. Search was not limited by year of publication so all articles archived in the database would be retrieved. No article from before 2010 was identified. A total of 57 publications of the last decade were included, all of which support the use of presepsin as a biomarker for the assessment of septic patients. It has been used alone or in combination with commonly used biomarkers in the evaluation of patients with sepsis in settings such as the emergency department and the intensive care unit. It is useful in the initial workup of patients with suspected sepsis in the emergency setting and may be a predictive factor of mortality and the most severe complication of sepsis. Presepsin seems to be a valuable tool for the laboratory workup of sepsis, especially when used in conjunction with other biomarkers and clinical rating scores with an established role in this population. Further research is needed to evaluate the clinical implications of utilizing presepsin measurements in the workup of sepsis.
- Open Access
- 22 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Correlation of Positive Blood Cultures with Peripherally Inserted Central Catheter Line Infection in Oncology Patients
Introduction: The use of peripherally inserted central catheter (PICC) lines offers several advantages compared to traditional central venous catheters (CVCs) as the insertion procedure is minimally invasive, they may be retained safely for longer periods of time, and their use is associated with fewer catheter-related infections. Their use in patients suffering from a malignant disease is common but may pose a greater risk of complications due to the severe immunosuppression associated with treatment. This study was conducted to evaluate the safety of PICC lines in this group. Methods: This was a retrospective study of oncology patients being treated in a Mediterranean tertiary center. Patients with PICC lines were enrolled in the study if a positive blood culture necessitated the removal of the PICC and subsequent culture of the PICC tip. A comparison was conducted between patients with positive and negative PICC cultures. Results: Thirty patients were included, four of whom had a positive PICC culture. The most commonly isolated pathogens were coagulase-negative Staphylococci and Corynebacteria. No statistically significant difference was noted in white blood cell (WBC) counts, C-reactive protein (CRP), and Michigan PICC central line associated bloodstream infection (MPC) score between the two groups. Staphylococcus epidermidis was the most commonly isolated pathogen. Discussion: Though limited by a small sample size and the retrospective design, the findings of this study seem to corroborate existing literature on the subject which suggests that the use of PICC lines in oncology patients is feasible and does not pose unacceptable risk. Further research is indicated to determine subgroups which may be at greater risk of PICC related infections.
- 22 January 2021
- Published by Springer Nature in Cureus
- Vol. 13 (1)
Open AccessCorrelation of Positive Blood Cultures with Peripherally Inserted Central Catheter Line Infection in Oncology Patients
Introduction: The use of peripherally inserted central catheter (PICC) lines offers several advantages compared to traditional central venous catheters (CVCs) as the insertion procedure is minimally invasive, they may be retained safely for longer periods of time, and their use is associated with fewer catheter-related infections. Their use in patients suffering from a malignant disease is common but may pose a greater risk of complications due to the severe immunosuppression associated with treatment. This study was conducted to evaluate the safety of PICC lines in this group. Methods: This was a retrospective study of oncology patients being treated in a Mediterranean tertiary center. Patients with PICC lines were enrolled in the study if a positive blood culture necessitated the removal of the PICC and subsequent culture of the PICC tip. A comparison was conducted between patients with positive and negative PICC cultures. Results: Thirty patients were included, four of whom had a positive PICC culture. The most commonly isolated pathogens were coagulase-negative Staphylococci and Corynebacteria. No statistically significant difference was noted in white blood cell (WBC) counts, C-reactive protein (CRP), and Michigan PICC central line associated bloodstream infection (MPC) score between the two groups. Staphylococcus epidermidis was the most commonly isolated pathogen. Discussion: Though limited by a small sample size and the retrospective design, the findings of this study seem to corroborate existing literature on the subject which suggests that the use of PICC lines in oncology patients is feasible and does not pose unacceptable risk. Further research is indicated to determine subgroups which may be at greater risk of PICC related infections.
- 1 January 2021
- Vol. 25 (14) , 4746-4756
Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic
OBJECTIVE: Akathisia is among the most troubling effects of psychiatric drugs as it is associated with significant distress on behalf of the patients. and it limits treatment adherence. Though it most commonly presents during treatment with antipsychotic drugs which block dopamine D2 receptors. Akathisia has also been reported during treatment with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), stimulants, mirtazapine, tetrabenazine and other drugs. MATERIALS AND METHODS: This article was designed as a narrative review on akathisia with a focus on its clinical presentation, pathophysiology and management. A PubMed search for akathisia was conducted which returned 8481 articles. RESULTS: Akathisia is experienced as severe restlessness commonly accompanied by dysphoria and purposeless movement which relieves subjective tension. It has been attributed to an imbalance between dopaminergic and noradrenergic neurotransmission in the basal ganglia. Acute akathisia commonly resolves upon treatment discontinuation but tardive and chronic akathisia may persist after the causative agent is withdrawn and prove resistant to pharmacological treatment. Even drugs which induce no other extrapyramidal side effects (such as clozapine, quetiapine, aripiprazole and cariprazine) may induce akathisia. A high index of suspicion should be maintained in patients with motor disabilities, drug-induced parkinsonism and those under mechanical restraint. Propranolol and low-dose mirtazapine are the most thoroughly studied pharmacological interventions for akathisia, though benzodiazepines, voltage- gated calcium channel blockers (gabapentin. pregabalin) and opioids may be effective. CONCLUSIONS: Pharmacological management may pose a challenge in chronic akathisia. Rotation between different pharmacological management strategies may be optimal in resistant cases. Discontinuation of the causative drug and use of b-blockers, mirtazapine, benzo-diazepines or gabapentinoids for symptomatic relief is the basis of management.
- 1 January 2021
- Vol. 25 (14) , 4746-4756
Pathophysiology and management of Akathisia 70 years after the introduction of the chlorpromazine, the first antipsychotic
OBJECTIVE: Akathisia is among the most troubling effects of psychiatric drugs as it is associated with significant distress on behalf of the patients. and it limits treatment adherence. Though it most commonly presents during treatment with antipsychotic drugs which block dopamine D2 receptors. Akathisia has also been reported during treatment with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), stimulants, mirtazapine, tetrabenazine and other drugs. MATERIALS AND METHODS: This article was designed as a narrative review on akathisia with a focus on its clinical presentation, pathophysiology and management. A PubMed search for akathisia was conducted which returned 8481 articles. RESULTS: Akathisia is experienced as severe restlessness commonly accompanied by dysphoria and purposeless movement which relieves subjective tension. It has been attributed to an imbalance between dopaminergic and noradrenergic neurotransmission in the basal ganglia. Acute akathisia commonly resolves upon treatment discontinuation but tardive and chronic akathisia may persist after the causative agent is withdrawn and prove resistant to pharmacological treatment. Even drugs which induce no other extrapyramidal side effects (such as clozapine, quetiapine, aripiprazole and cariprazine) may induce akathisia. A high index of suspicion should be maintained in patients with motor disabilities, drug-induced parkinsonism and those under mechanical restraint. Propranolol and low-dose mirtazapine are the most thoroughly studied pharmacological interventions for akathisia, though benzodiazepines, voltage- gated calcium channel blockers (gabapentin. pregabalin) and opioids may be effective. CONCLUSIONS: Pharmacological management may pose a challenge in chronic akathisia. Rotation between different pharmacological management strategies may be optimal in resistant cases. Discontinuation of the causative drug and use of b-blockers, mirtazapine, benzo-diazepines or gabapentinoids for symptomatic relief is the basis of management.
- 1 January 2021
- Vol. 25 (13) , 4514-4519
Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa
OBJECTIVE: Drugs affecting dopaminergic neurotransmission may exert toxic and beneficial effects that persist after discontinuation by modulating gene expression in key brain regions. Drug addiction, cravings and the tardive symptoms associated with chronic exposure to antipsychotics are among the most common processes attributed to long-term dopaminergic neurotoxicity. The purpose of this review was to investigate the mechanisms of dopaminergic neurotoxicity induced by neuroleptic drugs, dopamine agonists, levodopa, stimulants and known dopaminergic neurotoxins MATERIALS AND METHODS: A PubMed search for each of the dopaminergic compounds in question was carried out. The heterogenous nature of the relevant preclinical studies precluded a systematic review, so a narrative review was carried out. RESULTS: The dopaminergic neurotoxins 6-oxidopamine and 1-methyl-4-phenyl-tetrahydropyridine (MPTP) promote oxidative stress and inhibit mitochondrial function, while their affinity for the dopamine transporter ensures they are attain toxic intracellular concentrations exclusively in dopaminergic neurons. Stimulants which inhibit the vesicular monoamine transporter such as amphetamine and its derivatives promote oxidative stress by greatly increasing intracellular dopamine concentrations and enabling dopamine autooxidation. Antipsychotics increase dopamine release and turnover by blocking autoinhibitory D2 receptors and lead to upregulation of post-synaptic D2 receptors. Dopamine agonists may slow the progression of Parkinson's disease by reducing dopamine turnover, but downregulation of D2 receptors may underlie their behavioural toxicity. CONCLUSIONS: Though the mechanisms have not been completely elucidated yet, it seems drugs which affect dopaminergic neuro-transmission may exert long-term effects which reverse slowly upon discontinuation, if at all. Until the nature of these changes is clear it would be best to utilize drugs which affect dopaminergic neurotransmission cautiously especially if prolonged treatment is required.
- 1 January 2021
- Vol. 25 (13) , 4514-4519
Converging dopaminergic neurotoxicity mechanisms of antipsychotics, methamphetamine and levodopa
OBJECTIVE: Drugs affecting dopaminergic neurotransmission may exert toxic and beneficial effects that persist after discontinuation by modulating gene expression in key brain regions. Drug addiction, cravings and the tardive symptoms associated with chronic exposure to antipsychotics are among the most common processes attributed to long-term dopaminergic neurotoxicity. The purpose of this review was to investigate the mechanisms of dopaminergic neurotoxicity induced by neuroleptic drugs, dopamine agonists, levodopa, stimulants and known dopaminergic neurotoxins MATERIALS AND METHODS: A PubMed search for each of the dopaminergic compounds in question was carried out. The heterogenous nature of the relevant preclinical studies precluded a systematic review, so a narrative review was carried out. RESULTS: The dopaminergic neurotoxins 6-oxidopamine and 1-methyl-4-phenyl-tetrahydropyridine (MPTP) promote oxidative stress and inhibit mitochondrial function, while their affinity for the dopamine transporter ensures they are attain toxic intracellular concentrations exclusively in dopaminergic neurons. Stimulants which inhibit the vesicular monoamine transporter such as amphetamine and its derivatives promote oxidative stress by greatly increasing intracellular dopamine concentrations and enabling dopamine autooxidation. Antipsychotics increase dopamine release and turnover by blocking autoinhibitory D2 receptors and lead to upregulation of post-synaptic D2 receptors. Dopamine agonists may slow the progression of Parkinson's disease by reducing dopamine turnover, but downregulation of D2 receptors may underlie their behavioural toxicity. CONCLUSIONS: Though the mechanisms have not been completely elucidated yet, it seems drugs which affect dopaminergic neuro-transmission may exert long-term effects which reverse slowly upon discontinuation, if at all. Until the nature of these changes is clear it would be best to utilize drugs which affect dopaminergic neurotransmission cautiously especially if prolonged treatment is required.
- Open Access
- 1 January 2021
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 13 (3) , 133-142
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
- 1 January 2021
- Published by Elmer Press, Inc. in Journal of Clinical Medicine Research
- Vol. 13 (3) , 133-142
Open AccessSoluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
- 1 January 2021
- Vol. 25 (1) , 466-479
Procalcitonin and sepsis in the Emergency Department: an update
OBJECTIVE: Due to significant mortality and morbidity which may be reduced by prompts treatment. there is great interest in determining an ideal biomarker for the diagnosis of sepsis upon presentation to the Emergency Department. The most specific test is a positive blood culture. but its sensitivity is very low, and the results are usually available 2 days after sampling. For this reason, research is conducted into serum biomarkers with greater sensitivity for which results can be available within hours of presentation. High initial procalcitonin levels are a sensitive marker of bacterial infection, and the degree of procalcitonin elevation may determine which patients are at greater risk for adverse outcomes (mortality or ICU admission). The purpose of this narrative review is to evaluate the utility of procalcitonin as a diagnostic marker of sepsis in the emergency department and the use of procalcitonin-guided management algorithms. MATERIALS AND METHODS: A PubMed search was conducted in June 2020 for procalcitonin, resulting in the retrieval of 371 articles which were screened for relevance. 48 articles were included in the review. CONCLUSIONS: Procalcitonin elevation may be used as an indication for initiation of antibiotic treatment, and antibiotics may be discontinued once procalcitonin normalizes. This approach leads to reduced antibiotic consumption, but it is not yet clear whether it ensures better outcomes for patients. Procalcitonin in centers where it is available could be a useful diagnostic and prognostic biomarker for patients presenting to the Emergency Department with symptoms suggestive of sepsis. Further research is however required to determine whether the use of procalcitonin measurements in management algorithms leads to improved patient outcomes.
- 1 January 2021
- Vol. 25 (1) , 466-479
Procalcitonin and sepsis in the Emergency Department: an update
OBJECTIVE: Due to significant mortality and morbidity which may be reduced by prompts treatment. there is great interest in determining an ideal biomarker for the diagnosis of sepsis upon presentation to the Emergency Department. The most specific test is a positive blood culture. but its sensitivity is very low, and the results are usually available 2 days after sampling. For this reason, research is conducted into serum biomarkers with greater sensitivity for which results can be available within hours of presentation. High initial procalcitonin levels are a sensitive marker of bacterial infection, and the degree of procalcitonin elevation may determine which patients are at greater risk for adverse outcomes (mortality or ICU admission). The purpose of this narrative review is to evaluate the utility of procalcitonin as a diagnostic marker of sepsis in the emergency department and the use of procalcitonin-guided management algorithms. MATERIALS AND METHODS: A PubMed search was conducted in June 2020 for procalcitonin, resulting in the retrieval of 371 articles which were screened for relevance. 48 articles were included in the review. CONCLUSIONS: Procalcitonin elevation may be used as an indication for initiation of antibiotic treatment, and antibiotics may be discontinued once procalcitonin normalizes. This approach leads to reduced antibiotic consumption, but it is not yet clear whether it ensures better outcomes for patients. Procalcitonin in centers where it is available could be a useful diagnostic and prognostic biomarker for patients presenting to the Emergency Department with symptoms suggestive of sepsis. Further research is however required to determine whether the use of procalcitonin measurements in management algorithms leads to improved patient outcomes.
- Open Access
- 3 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8) , e9536
Neuropsychiatric Effects of Antiviral Drugs
The adverse events of antiviral drugs are dose-dependent and often reversible. The nervous system is often affected and to date, many studies have been published regarding the central nervous system toxicity of antiviral agents. They may cause significant neuropsychiatric complications, which range from mild symptoms such as irritability and difficulty sleeping to severe complications such as depression, psychosis, and painful peripheral neuropathy, side effects which may necessitate discontinuation of treatment. The pathogenetic mechanisms may involve molecular targets common to other centrally active drugs, including human monoamine oxidase‐A (MAO‐A), serotonin receptors, gamma-aminobutyric acid (GABA) GABA-A receptors, 5-HT2A and 5-HT2C receptors and others. Notable examples include oseltamivir which may act as MAO inhibitor and efavirenz, which has an affinity for serotonin 5-HT2 and GABA-A receptors, the serotonin transporter, the MAO enzyme, and the vesicular monoamine transporter, with subjective effects which may be similar to those of the psychedelic hallucinogen lysergic acid diethylamide (LSD). Other antiviral drugs with prominent nervous system effects include nucleoside reverse transcriptase inhibitors, which are associated with the development of peripheral neuropathy after prolonged use (an effect strongly associated with older drugs which have since fallen into disfavor such as stavudine) and interferons, which may cause depression. Clinicians should be familiar with such adverse effects in order to recognise them promptly once they occur and manage them appropriately.
- 3 August 2020
- Published by Springer Nature in Cureus
- Vol. 12 (8) , e9536
Open AccessNeuropsychiatric Effects of Antiviral Drugs
The adverse events of antiviral drugs are dose-dependent and often reversible. The nervous system is often affected and to date, many studies have been published regarding the central nervous system toxicity of antiviral agents. They may cause significant neuropsychiatric complications, which range from mild symptoms such as irritability and difficulty sleeping to severe complications such as depression, psychosis, and painful peripheral neuropathy, side effects which may necessitate discontinuation of treatment. The pathogenetic mechanisms may involve molecular targets common to other centrally active drugs, including human monoamine oxidase‐A (MAO‐A), serotonin receptors, gamma-aminobutyric acid (GABA) GABA-A receptors, 5-HT2A and 5-HT2C receptors and others. Notable examples include oseltamivir which may act as MAO inhibitor and efavirenz, which has an affinity for serotonin 5-HT2 and GABA-A receptors, the serotonin transporter, the MAO enzyme, and the vesicular monoamine transporter, with subjective effects which may be similar to those of the psychedelic hallucinogen lysergic acid diethylamide (LSD). Other antiviral drugs with prominent nervous system effects include nucleoside reverse transcriptase inhibitors, which are associated with the development of peripheral neuropathy after prolonged use (an effect strongly associated with older drugs which have since fallen into disfavor such as stavudine) and interferons, which may cause depression. Clinicians should be familiar with such adverse effects in order to recognise them promptly once they occur and manage them appropriately.
- Open Access
- 27 April 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (2) , 242-245
Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain
Even though the early reports from China provided advance warning of what was to come, the COVID-19 pandemic has spread throughout the world with devastating consequences. Emergency measures are being implemented to reduce the magnitude of the public health crisis, prevent healthcare facilities from becoming overwhelmed and reduce the death toll of the disease. Containment strategies to mitigate viral transmission and emergency measures to increase the capacity of each country to provide intensive care are at the forefront of the public health management of the epidemic, even though the detrimental social and psychological effects of quarantine are evident on a global scale. Optimal management of critically ill patients with COVID-19 is also unclear, and the initial suggestion for early intubation as in typical ARDS may have caused significant harm. The management of mild cases of confirmed infection is another point of controversy, as drugs which may be repurposed for COVID-19 treatment have significant, potentially irreversible toxic effects and their use in mild cases of a viral illness which is typically self-limited may be harmful.
- 27 April 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (2) , 242-245
Open AccessManagement of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain
Even though the early reports from China provided advance warning of what was to come, the COVID-19 pandemic has spread throughout the world with devastating consequences. Emergency measures are being implemented to reduce the magnitude of the public health crisis, prevent healthcare facilities from becoming overwhelmed and reduce the death toll of the disease. Containment strategies to mitigate viral transmission and emergency measures to increase the capacity of each country to provide intensive care are at the forefront of the public health management of the epidemic, even though the detrimental social and psychological effects of quarantine are evident on a global scale. Optimal management of critically ill patients with COVID-19 is also unclear, and the initial suggestion for early intubation as in typical ARDS may have caused significant harm. The management of mild cases of confirmed infection is another point of controversy, as drugs which may be repurposed for COVID-19 treatment have significant, potentially irreversible toxic effects and their use in mild cases of a viral illness which is typically self-limited may be harmful.
- Open Access
- 21 January 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (1)
Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?
Severe COVID-19 illness is characterised by the development of Acute Respiratory Distress Syndrome (ARDS), for which the mainstay of treatment is represented by mechanical ventilation. Mortality associated with ARDS due to other causes is in the range of 40-60%, but currently available data are not yet sufficient to draw safe conclusions on the prognosis of COVID-19 patients who require mechanical ventilation. Based on data from cohorts of the related coronavirus-associated illnesses, that is to say Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), prognosis would seem to be worse than ARDS due to other causes such as trauma and other infections. Discussion of prognosis is central to obtaining informed consent for intubation, but in the absence of definitive data it is not clear exactly what this discussion should entail.
- 21 January 2020
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 90 (1)
Open AccessIntubation and mechanical ventilation of patients with COVID-19: what should we tell them?
Severe COVID-19 illness is characterised by the development of Acute Respiratory Distress Syndrome (ARDS), for which the mainstay of treatment is represented by mechanical ventilation. Mortality associated with ARDS due to other causes is in the range of 40-60%, but currently available data are not yet sufficient to draw safe conclusions on the prognosis of COVID-19 patients who require mechanical ventilation. Based on data from cohorts of the related coronavirus-associated illnesses, that is to say Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), prognosis would seem to be worse than ARDS due to other causes such as trauma and other infections. Discussion of prognosis is central to obtaining informed consent for intubation, but in the absence of definitive data it is not clear exactly what this discussion should entail.